The global market for infectious disease treatments is expected to grow from $72.5 billion in 2025 and is projected to reach $101 billion by the end of 2030, at a compound annual growth rate (CAGR) of 6.9% during the forecast period of 2025 to 2030.
Despite advances in healthcare, infectious diseases continue to have a devastating impact on public health. In any given year, billions of people worldwide contract infectious diseases. Based on information provided by the World Health Organization (WHO), AIDS, malaria and tuberculosis combined are responsible for half of the deaths stemming from infectious diseases, with Africa and Southeast Asia bearing the most significant burden.
Leading companies working in the domain of infectious diseases include Abbott, Roche Diagnostics, Danaher Corp., Gilead Sciences, Sanofi, GSK plc, Pfizer, CSL, Merck and Co. Inc., and Johnson and Johnson Services Inc.
Market Dynamics
The infectious disease treatment market is driven by global health challenges and advances in medical science. Infectious diseases such as HIV, hepatitis, TB, and influenza continue to pose significant health threats worldwide. The growing challenge of drug resistance highlights critical gaps in current treatment, reinforcing the need for continuous investment and innovation in this space. Factors such as increased global travel, urbanization, and climate change contribute to the spread of infectious diseases. Aging populations and the accompanying chronic health conditions also contribute to increased vulnerability to infectious diseases.
Emerging Trends
Long-acting injectables and antivirals are emerging as transformative innovations in the treatment and prevention of infectious diseases, addressing challenges like poor adherence and frequent dosing. Selftesting kits are rapidly gaining traction, offering individuals convenient, private, and timely diagnostic options. Interest in multiplex PCR testing has increased in the past few years. Combination therapies are increasingly used to combat resistance and improve outcomes.
The report’s estimates of the infectious disease market include global revenue ($ millions) for the base year of 2024, estimates for 2025, and data for the forecast period of 2026 through 2030. The report focuses on the major trends, challenges and opportunities in the market and vendor landscape. It also covers the new products, acquisitions, and collaborations related to the market. The report also analyzes environmental, social, and corporate governance (ESG) developments.
The report concludes with an analysis of the competitive landscape, which provides a ranking by market share of leading companies in the market. There is also a section of profiles of the leading companies.
Outside the scope of the report are vector/mosquito control approaches, strategies and products, drugs used for symptomatic treatment and not for the elimination of the virus from the host, and details on suppliers of generics and non-branded generics. Also excluded are markets for hospital-based diagnosis that are not carried out by kits (for example, malaria slide smear-based tests), as well as discussion of the spread of vector-borne infection (such as malaria) via blood transfusion.
Despite advances in healthcare, infectious diseases continue to have a devastating impact on public health. In any given year, billions of people worldwide contract infectious diseases. Based on information provided by the World Health Organization (WHO), AIDS, malaria and tuberculosis combined are responsible for half of the deaths stemming from infectious diseases, with Africa and Southeast Asia bearing the most significant burden.
Leading companies working in the domain of infectious diseases include Abbott, Roche Diagnostics, Danaher Corp., Gilead Sciences, Sanofi, GSK plc, Pfizer, CSL, Merck and Co. Inc., and Johnson and Johnson Services Inc.
Market Dynamics
The infectious disease treatment market is driven by global health challenges and advances in medical science. Infectious diseases such as HIV, hepatitis, TB, and influenza continue to pose significant health threats worldwide. The growing challenge of drug resistance highlights critical gaps in current treatment, reinforcing the need for continuous investment and innovation in this space. Factors such as increased global travel, urbanization, and climate change contribute to the spread of infectious diseases. Aging populations and the accompanying chronic health conditions also contribute to increased vulnerability to infectious diseases.
Emerging Trends
Long-acting injectables and antivirals are emerging as transformative innovations in the treatment and prevention of infectious diseases, addressing challenges like poor adherence and frequent dosing. Selftesting kits are rapidly gaining traction, offering individuals convenient, private, and timely diagnostic options. Interest in multiplex PCR testing has increased in the past few years. Combination therapies are increasingly used to combat resistance and improve outcomes.
Report Scope
This report offers an analysis of the global market for infectious disease therapeutics, vaccines, and diagnostics. The infectious diseases covered in the report include human immunodeficiency virus (HIV) infection, seasonal influenza (including influenza A and B), hepatitis B, hepatitis C, respiratory syncytial virus (RSV) infection, tuberculosis (TB), herpes simplex virus (HSV) infection, malaria, rotavirus infection, and viral hemorrhagic fevers such as yellow fever, dengue, Lassa fever, Ebola fever, and Zika fever.The report’s estimates of the infectious disease market include global revenue ($ millions) for the base year of 2024, estimates for 2025, and data for the forecast period of 2026 through 2030. The report focuses on the major trends, challenges and opportunities in the market and vendor landscape. It also covers the new products, acquisitions, and collaborations related to the market. The report also analyzes environmental, social, and corporate governance (ESG) developments.
The report concludes with an analysis of the competitive landscape, which provides a ranking by market share of leading companies in the market. There is also a section of profiles of the leading companies.
Outside the scope of the report are vector/mosquito control approaches, strategies and products, drugs used for symptomatic treatment and not for the elimination of the virus from the host, and details on suppliers of generics and non-branded generics. Also excluded are markets for hospital-based diagnosis that are not carried out by kits (for example, malaria slide smear-based tests), as well as discussion of the spread of vector-borne infection (such as malaria) via blood transfusion.
The report includes:
- 53 data tables and 69 additional tables
- A review of the global market for infectious disease treatments in the healthcare and pharmaceutical industry
- Analyses of the global market trends, with sales data from 2022-2024, estimates for 2025, and projected CAGRs through 2030
- Evaluation and forecast of the overall market size in terms of dollar value terms, and corresponding market share analysis based on product type, disease type, and geographic region
- An evaluation of the market potential for infectious disease treatments, opportunities and gaps, estimating current and future demand
- Discussion of new drugs and innovations in chemical compounds, vaccines and biologicals and diagnostic kits that are recently launched or in development
- Review of key patent grants and new technologies related to innovations in infectious disease treatments
- Identification of challenges and discussion of how to overcome these to be able to reach commercialization potential, and ESG trends of the market
- Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies and a relevant patent analysis
- Profiles of the leading companies, includingGilead Sciences Inc., GSK plc., Sanofi, Merck & Co. Inc., and Abbott
Table of Contents
Chapter 1 Executive Summary
Chapter 2 Market Overview
Chapter 3 Market Dynamics
Chapter 4 Regulatory Landscape
Chapter 5 Emerging Technologies and Developments
Chapter 6 Market Segmentation Analysis
Chapter 7 Competitive Intelligence
Chapter 8 Sustainability in Infectious Disease Treatment Industry: An ESG Perspective
Chapter 9 Appendix
List of Tables
List of Figures
Companies Mentioned
- Abbott
- AbbVie Inc.
- CSL
- Danaher Corp.
- F. Hoffmann-La Roche Ltd.
- Gilead Sciences Inc.
- GSK PLC
- Johnson & Johnson Services Inc.
- Merck & Co. Inc.
- Molbio Diagnostics Ltd.
- Orasure Technologies Inc.
- Pfizer Inc.
- Sanofi
- Serum Institute of India Pvt. Ltd.
- Siemens Heathineers AG
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 186 |
| Published | July 2025 |
| Forecast Period | 2025 - 2030 |
| Estimated Market Value ( USD | $ 72.5 Billion |
| Forecasted Market Value ( USD | $ 101 Billion |
| Compound Annual Growth Rate | 6.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
